The dynamic Cell & Gene Therapy community in the UK offers huge potential for the development of innovative ATMPs for medical treatments. However, barriers in early phase development are high. In addition to scientific expertise and research funding, it requires millions of pounds in laboratory space, manufacturing equipment, and access to biological raw materials. To address these issues and provide an environment SMEs can use to translate their research through to early-stage clinical development, Anthony Nolan Cell and Gene Therapy Services, Miltenyi Biotec Ltd., and Medical Technologies Innovation Facility (MTIF) join forces. This partnership brings together access to cellular raw materials, state-of-the-art research facilities, manufacturing equipment and expertise from three established members of the UK CGT community. The Partners will provide full support to facilitate the cost-effective development of advanced therapy by overcoming the need for high investment in the early development phase and share their collective expertise and proven capabilities to expedite development from discovery to clinical application. The Partners recognise that Cell and Gene Therapies hold significant promise to revolutionise the way many diseases are treated, as well as offering entirely new treatment options for patients. Indeed, the UK Government anticipates approximately 10,000 patients annually will be treated using these new methods by 2028.
“This collaboration seeks to help overcome many challenges faced in early ATMP development to enhance and accelerate the development and translation of innovative treatments that could have a significant impact on patients, we are excited to be able to support developers and innovators move from concept to treatment”
Dr. Roger Horton, Cell and Gene Therapy Services, Clinical Delivery Lead, at Anthony Nolan.
“The collective expertise and proven capabilities within this partnership will undoubtedly support organisations of all sizes to accelerate their cell therapy developments. MTIF are delighted to assist the development of such life-changing therapies and potential treatment of previously intractable diseases.”
Professor Mike Hannay, Managing Director at MTIF.
“Ultimately, our hope is that this partnership will be instrumental in further clinical developments that will both advance scientific understanding of severe diseases, empower new therapies and make them available to as many patients as possible”
Michele Giroux, General Manager Miltenyi Biotec Ltd..
We are extremely excited to begin this collaboration, working together to make easier patient access to CGT a reality.
About Anthony Nolan Cell and Gene Therapy Services
Anthony Nolan is the pioneering charity that saves the lives of people with blood cancer and blood disorders
who need a stem cell transplant. Anthony Nolan’s Cell and Gene Therapy Services aim to facilitate ethical
research and development through the sourcing and supply of donor starting materials to researchers and
developers. With a register of over 850,000 donors, a cord blood bank, and four decades of experience
providing stem cells, Anthony Nolan has the infrastructure, the expertise, and the skills to support the needs
of the cell and gene therapy industry.
Website: www.anthonynolan.org
LinkedIn: www.linkedin.com/showcase/anthony-nolan-cell-&-gene-therapy-services/
Contact: katie.griffee@anthonynolan.org
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance
cellular therapy. Our innovative technologies enable solutions for cellular research, cell therapy, and cell
manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell
biology, neuroscience, and cancer. Miltenyi Biotec has more than 3,500 employees in 28 countries.
Website: www.miltenyibiotec.com
LinkedIn: www.linkedin.com/company/miltenyi-biotec/
Contact: dawnf@miltenyi.com
About MTIF
MTIF is a medical devices and advanced materials technology facility offering ‘ bench to bedside ‘ research and development services for innovative medical technologies, cell and tissue therapies and pharmaceuticals as well as in thin film technology, printed electronics, nano-photonics, opto-electronic properties of materials and devices and laser processing. With ISO 13485 certified facilities MTIF can design and deliver end-to-end development projects, including product design, product development, technical dossier compilation, process scale-up and facilities for clinical trial manufacture.
Website : www.mtif.co.uk
Linkedin: www.linkedin.com/company/mtif/
Contact : max.bardwell@ntu.ac.uk